BRCA1 and cancer: In recent years, DNA damage repair deficiency has been successfully used in cancer therapy; for instance, cancers with MSI microsatellite instability) can be treated with immune checkpoint blockade-based immunotherapies, while genomic mutations of BRCA1/2 or HRR homologous recombination repair) are targets of PARP inhibitors.